Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
The NDA follows a recent positive pre-NDA meeting with the FDA   The NDA for Talicia ® is eligible for six-month priority review   Talicia ® is eligible for a total of eight years of U.S. market exclusivity, in addition to patent protection until at least 2034   RedHill continues to strengthen its ...
View HTML
Toggle Summary RedHill Biopharma to Host First Quarter 2019 Financial Results Conference Call on May 7, 2019
TEL-AVIV, Israel and RALEIGH, N.C. , April 30, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ( Nasdaq : RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that it will report ...
View HTML
Toggle Summary RedHill Biopharma to Present at Three Conferences in April
TEL-AVIV, Israel and RALEIGH, N.C. , April 04, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that the Company will ...
View HTML
Toggle Summary RedHill Biopharma to Present at the BIO-Europe Spring 2019 Conference
TEL-AVIV, Israel and RALEIGH, N.C. , March 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. ...
View HTML
Toggle Summary RedHill Biopharma to Present at the 31st Annual ROTH Conference
TEL-AVIV, Israel and RALEIGH, N.C. , March 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. ...
View HTML
Toggle Summary RedHill Biopharma Announces New European and Japanese Patents for Talicia®
The European and Japanese patent applications have been accepted and, once granted, are expected to be valid until 2034   U.S. NDA for Talicia ® on track for potential submission in H1/2019 and U.S. commercial launch in Q4/2019   Talicia ® was granted QIDP designation, including eligibility for ...
View HTML
Toggle Summary RedHill Biopharma Provides Full-Year 2018 Financial Results and Operational Highlights
TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today reported its full-year 2018 ...
View HTML
Toggle Summary RedHill Biopharma to Host Full-Year 2018 Financial Results Conference Call on February 26, 2019
TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Strengthens Management Team with Appointment of Rick D. Scruggs as Chief Operating Officer, U.S. Operations
TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today ...
View HTML
Toggle Summary RedHill Biopharma to Present at the 8th Annual SVB Leerink Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today ...
View HTML